Literature DB >> 24598852

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Mohamad Mohty1, Jean-Luc Harousseau.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24598852      PMCID： PMC3943303          DOI： 10.3324/haematol.2013.096149

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  68 in total

Review 1.  Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Authors:  Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2009-06-18       Impact factor: 91.245

2.  Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.

Authors:  X Leleu; G Fouquet; B Hebraud; M Roussel; D Caillot; M L Chrétien; B Arnulf; R Szalat; L Garderet; L Benajiba; B Pegourie; C Regny; B Royer; A Caulier; A M Stoppa; S Garciaz; C Touzeau; C Chaleteix; J P Fermand; H A Loiseau; T Facon; M Attal; P Moreau
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528

Review 3.  Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.

Authors:  Philippe Moreau; Hervé Avet-Loiseau; Jean-Luc Harousseau; Michel Attal
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Authors:  Michele Cavo; S Vincent Rajkumar; Antonio Palumbo; Philippe Moreau; Robert Orlowski; Joan Bladé; Orhan Sezer; Heinz Ludwig; Meletios A Dimopoulos; Michel Attal; Pieter Sonneveld; Mario Boccadoro; Kenneth C Anderson; Paul G Richardson; William Bensinger; Hans E Johnsen; Nicolaus Kroeger; Gösta Gahrton; P Leif Bergsagel; David H Vesole; Hermann Einsele; Sundar Jagannath; Ruben Niesvizky; Brian G M Durie; Jesus San Miguel; Sagar Lonial
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

5.  Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Authors:  Roland Fenk; Vanessa Liese; Florian Neubauer; Ingmar Bruns; Mustafa Kondakci; Sebastian Balleisen; Christian Saure; Thomas Schröder; Rainer Haas; Guido Kobbe
Journal:  Leuk Lymphoma       Date:  2011-06-10

6.  Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Authors:  P Tosi; E Zamagni; S Ronconi; M Benni; M R Motta; S Rizzi; S Tura; M Cavo
Journal:  Leukemia       Date:  2000-07       Impact factor: 11.528

7.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

8.  Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Authors:  Ulf-Henrik Mellqvist; Peter Gimsing; Oyvind Hjertner; Stig Lenhoff; Edward Laane; Kari Remes; Hlif Steingrimsdottir; Niels Abildgaard; Lucia Ahlberg; Cecilie Blimark; Inger Marie Dahl; Karin Forsberg; Tobias Gedde-Dahl; Henrik Gregersen; Astrid Gruber; Nina Guldbrandsen; Einar Haukås; Kristina Carlson; Ann Kristin Kvam; Hareth Nahi; Roald Lindås; Niels Frost Andersen; Ingemar Turesson; Anders Waage; Jan Westin
Journal:  Blood       Date:  2013-04-24       Impact factor: 22.113

9.  TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Authors:  John D Shaughnessy; Yiming Zhou; Jeff Haessler; Frits van Rhee; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Br J Haematol       Date:  2009-08-21       Impact factor: 6.998

10.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941
View more
  17 in total

Review 1.  First line vs delayed transplantation in myeloma: Certainties and controversies.

Authors:  Annamaria Brioli
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Developments in the Field of Myeloma in the Last Decade.

Authors:  Tapan K Saikia
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-17       Impact factor: 0.900

Review 3.  The evolution of stem-cell transplantation in multiple myeloma.

Authors:  Sarakshi Mahajan; Nidhi Tandon; Shaji Kumar
Journal:  Ther Adv Hematol       Date:  2018-03-05

4.  Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.

Authors:  Daria Ripani; Carmelo Caldarella; Tommaso Za; Daniele Antonio Pizzuto; Elena Rossi; Valerio De Stefano; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-27       Impact factor: 9.236

Review 5.  Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Authors:  Shahzad Raza; Rachael A Safyan; Evan Rosenbaum; Alex S Bowman; Suzanne Lentzsch
Journal:  Ther Adv Hematol       Date:  2016-12-09

Review 6.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

7.  Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.

Authors:  Barbara Skopec; Matevz Skerget; Darja Zontar; Vesna Zadnik; Samo Zver
Journal:  Wien Klin Wochenschr       Date:  2017-04-24       Impact factor: 1.704

Review 8.  Initial Therapeutic Approaches to Patients with Multiple Myeloma.

Authors:  Hadi E Berbari; Shaji K Kumar
Journal:  Adv Ther       Date:  2021-06-18       Impact factor: 3.845

9.  Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

Authors:  Edvan de Queiroz Crusoe; Fabiana Higashi; Gracia Aparecida Martinez; José Carlos Barros; Marcelo Bellesso; Marina Rossato; Ana Cinira F Marret; Carlos Sérgio Chiattone; Vania Tietsch de Moraes Hungria
Journal:  Rev Bras Hematol Hemoter       Date:  2016-07-29

10.  Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Authors:  Matevz Skerget; Barbara Skopec; Darja Zontar; Peter Cernelc
Journal:  Radiol Oncol       Date:  2016-05-12       Impact factor: 2.991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.